Free Trial

Canopy Growth (TSE:WEED) Reaches New 52-Week Low After Analyst Downgrade

Canopy Growth logo with Medical background

Canopy Growth Corp (TSE:WEED - Get Free Report)'s stock price reached a new 52-week low during trading on Monday after ATB Capital lowered their price target on the stock from C$4.00 to C$3.20. ATB Capital currently has an underperform rating on the stock. Canopy Growth traded as low as C$2.74 and last traded at C$2.82, with a volume of 2140477 shares traded. The stock had previously closed at C$2.89.

Separately, Canaccord Genuity Group decreased their target price on Canopy Growth from C$2.50 to C$1.50 and set a "sell" rating on the stock in a report on Monday. Four research analysts have rated the stock with a sell rating and one has issued a hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Reduce" and an average target price of C$5.40.

Get Our Latest Report on WEED

Canopy Growth Stock Up 4.7 %

The firm has a fifty day moving average of C$3.72 and a 200-day moving average of C$5.84. The company has a quick ratio of 2.32, a current ratio of 1.39 and a debt-to-equity ratio of 120.38. The firm has a market cap of C$431.13 million, a P/E ratio of -0.39, a price-to-earnings-growth ratio of -0.01 and a beta of 1.79.

About Canopy Growth

(Get Free Report)

Canopy Growth Corporation, together with its subsidiaries, engages in growing, possession, and sale of medical cannabis in Canada. Its products include dried flowers, oils and concentrates, softgel capsules, and hemps. The company offers its products under the Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, CraftGrow, and Foria brand names.

Featured Articles

Should You Invest $1,000 in Canopy Growth Right Now?

Before you consider Canopy Growth, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Canopy Growth wasn't on the list.

While Canopy Growth currently has a "Strong Sell" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Goldman Sachs' 2025 Market Outlook: Top 3 Stock Picks

Goldman Sachs' 2025 Market Outlook: Top 3 Stock Picks

As Wall Street's 2025 predictions roll in, Goldman Sachs is focusing on manufacturing, energy, and domestic producers as key sectors for growth.

Recent Videos

NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?
Marjorie Taylor Greene Bought THOUSANDS in Tesla Stock
The EXACT Date of Next Stock Market Crash

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines